Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe
PharmaJet, Inc. is investigating the immune response elicited by its mRNA COVID-19 vaccine, COMIRNATY®, administered via two different delivery methods: intradermal injection using the Tropis Needle-Free Injection System (NFIS) and traditional intramuscular injection. The study aims to assess the efficacy and safety of these delivery methods in a healthy adult population aged 18 to 50. Given the ongoing demand for effective COVID-19 vaccines and the potential advantages of needle-free delivery systems, successful outcomes could position PharmaJet favorably in the competitive vaccine market. The study's collaboration with Emory University may enhance credibility and provide access to additional research resources. However, the trial is not yet recruiting, which may delay market entry and impact investor confidence.
Indication: Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers
Modality: RNA therapy
Target: SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)
Sponsor: PharmaJet, Inc.
Source URL: ClinicalTrials.gov
Source updated: Apr 15, 2025
Ingested: Jun 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)
View original source fields
Condition raw: Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Condition normalized: Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)
Target normalized: SARS-CoV-2 Spike Protein (mRNA-based vaccine targeting immune response)